×
0 0.010886469673406 0.0528771384136859 0.0808709175738725 0.04199066874028 0.0544323483670296 0.04199066874028 0.046656298600311
Stockreport

Adamas Announces U.S. Commercial Launch of GOCOVRI™ the First and Only FDA-approved Medication for the Treatment of Dyskinesia in Parkinson’s Disease Patients

ADAMAS PHARMACEUTICALS (ADMS)  More Company Research Source: GlobeNewswire
Last adamas pharmaceuticals earnings: 8/2 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.adamaspharma.com/investors
PDF EMERYVILLE, Calif., Jan. 08, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced the full commercial launch of its flagship product, GOCOVRI™ (amantadine) extended release capsules, for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications. GOCOVRI was approved by the U.S. Food and Drug Administration (FDA) in August 2017, when it was granted seven years of orphan drug exclusivity, and has been available for physician and patient use since October 2017. Today’s launch marks the deployment of Adamas’ dedicated team of 59 neurology field sales professionals, who are focused on educating the Parkinson’s disease community about the benefit/safety profile of GOCOVRI. “The full commercial launch of GOCOVRI represents an important milestone for Adamas and will significantly expand awareness of GOCOVRI for both physicians and patients,” said Gregory T. Went, Ph. [Read more]

IMPACT SNAPSHOT EVENT TIME: ADMS
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
POST NEWS RANGE
%
PRICE CHANGE

PRICE CHANGE PERCENTAGE


S&P 500 (SPX)

%

VOLUME RATIO
%

VOLUME (SHARES)
TICKS

AVG SHARES PER TRADE

Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
ADMS alerts
from News Quantified
Opt-in for
ADMS alerts

from News Quantified
Opt-in for
ADMS alerts

from News Quantified